Cardurion Pharmaceuticals Announces Appointment of Peter Lawrence as President and Chief Executive Officer
April 15, 2020 07:30 AM Eastern Daylight Time BOSTON – (BUSINESS WIRE) – Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering [...]
Cardurion Pharmaceuticals Announces Investment from Polaris Partners and Appoints Amy Schulman to Board of Directors
BOSTON, Mass. – November 20, 2019 – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of heart failure and [...]
Cardurion Pharmaceuticals Presents Preclinical Data for CRD-733 at the American Heart Association Scientific Sessions and Announces Initiation of Phase 1b Study in Patients with Heart Failure
CRD-733 treatment reduced or reversed several markers of heart failure and reversed pressure overload-induced cardiac hypertrophy in animal models
November 12, 2018 09:00 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, [...]
Silvia Priori, M.D., Ph.D. Delivers the William Harvey Lecture on Basic Science
CAMBRIDGE, MASS. – [October 2, 2018] – The European Society of Cardiology Congress holds four specialized lectures each year and selects four renowned scientists who are seen by their peers as [...]
Cardurion Pharmaceuticals Announces Initiation of Phase 1 Study of CRD-733, a PDE-9 Inhibitor in Development for the Treatment of Heart Failure
CAMBRIDGE, MASS. – [September 20, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular [...]
Cardurion Pharmaceuticals Appoints Jeb Keiper to Its Board of Directors
CAMBRIDGE, MASS. – [August 16, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular [...]
